Following a full submission
AWMSG advice |
||
| Status: Superseded | ||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED JANUARY 2005. Refer to TA161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
||
|
||
Medicine details |
||
| Medicine name | teriparatide (Forsteo®) | |
| Formulation | 20 micrograms/80 microlitres solution for injection | |
| Reference number | 304 | |
| Indication | Treatment of established osteoporosis in postmenopausal women |
|
| Company | Eli Lilly & Co Ltd | |
| BNF chapter | Endocrine system | |
| Submission type | Full | |
| Status | Superseded | |
| AWMSG meeting date | 09/06/2004 | |
| Ratification by Welsh Government | 30/09/2004 | |
| Date of issue | 30/09/2004 | |
| NICE guidance | ||